Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.

Pharmacogenetics and genomics - 1 Jan 2013

Lubomirov Rubin, Arab-Alameddine Mona, Rotger Margalida, Fayet-Mello Aurélie, Martinez Raquel, Guidi Monia, di Iulio Julia, Cavassini Matthias, Günthard Huldrych F, Furrer Hansjakob, Marzolini Catia, Bernasconi Enos, Calmy Alexandra, Buclin Thierry, Decosterd Laurent A, Csajka Chantal, Telenti Amalio

Abstract excerpt

OBJECTIVES: Etravirine (ETV) is metabolized by cytochrome P450 (CYP) 3A, 2C9, and 2C19. Metabolites are glucuronidated by uridine diphosphate glucuronosyltransferases (UGT). To identify the potential impact of genetic and non-genetic factors involved in ETV metabolism, we carried out a two-step pharmacogenetics-based population pharmacokinetic study in HIV-1 infected individuals. MATERIALS AND METHODS: The study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to HIV Protease Inhibitors

Share to Nitriles

Share to Pyridazines

Share to Switzerland

Share to Tissue Distribution

Source

Identifiers

PMID: 23111422
DOI: 10.1097/FPC.0b013e32835ade82

Genes

POR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.PMID 23111422Read ↗

Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.Semantic proximity Read ↗

Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.Semantic proximity Read ↗

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.Semantic proximity Read ↗

Gene-gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients.Semantic proximity Read ↗

Pharmacogenetic considerations for HIV treatment in different ethnicities: an update.Semantic proximity Read ↗

Pharmacogenomics of Antiretroviral Drug Metabolism and TransportSemantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients.Semantic proximity Read ↗

Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.Semantic proximity Read ↗

Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ARTSemantic proximity Read ↗

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.Semantic proximity Read ↗

A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.